Review demonstrates curcumin’s neuroprotective effects in neurodegenerative diseases, enhancing its potential through innovative nanoparticle formulations. This advancement could significantly improve treatments for diseases like Parkinson’s, Alzheimer’s, and Multiple Sclerosis.
FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing
The FDA rejected Rocket Pharmaceuticals’ gene therapy for leukocyte adhesion deficiency-I (LAD-I), requesting “limited additional” manufacturing information. The company announced the … Sign up to
June 29, 2024